Skip to main content

Advertisement

Table 3 Hazard ratios of incident cardiovascular disease in the categories of body composition classified using A/G ratio

From: Sarcopenic obesity assessed using dual energy X-ray absorptiometry (DXA) can predict cardiovascular disease in patients with type 2 diabetes: a retrospective observational study

  HR (95% CI) p value
Univariate model
 Normal 1.00 (reference)
 Sarcopenia 1.43 (0.58–3.52) 0.439
 Obesity 1.56 (0.71–3.43) 0.269
 Sarcopenic obesity 4.50 (1.93–10.46) 0.006
Multivariate model
 Normal 1.00 (reference)
 Sarcopenia 1.88 (0.75–4.74) 0.179
 Obesity 0.98 (0.44–2.21) 0.969
 Sarcopenic obesity 2.63 (1.10–6.28) 0.030
 HDL cholesterol (mmol/l) 0.21 (0.08–0.56) 0.002
 HbA1c (%) 1.28 (1.09–1.49) 0.002
 eGFR (ml/min/1.73 m2) 0.97 (0.96–0.98) < 0.001
 ACEIs or ARBs 2.07 (1.11–3.86) 0.022
 DPP4 inhibitors 0.46 (0.23–0.91) 0.025
 History of CVD 2.85 (1.57–5.18) 0.001
Gender-adjusted multivariate model
 Normal 1.00 (reference)
 Sarcopenia 1.46 (0.57–3.74) 0.429
 Obesity 0.94 (0.42–2.10) 0.870
 Sarcopenic obesity 2.14 (0.88–5.21) 0.093
 HDL cholesterol (mmol/l) 0.23 (0.09–0.62) 0.003
 HbA1c (%) 1.28 (1.10–1.49) 0.001
 eGFR (ml/min/1.73 m2) 0.97 (0.96–0.96) < 0.001
 ACEIs or ARBs 2.18 (1.17–4.10) 0.014
 DPP4 inhibitors 0.46 (0.23–0.88) 0.020
 History of CVD 2.65 (1.44–4.87) 0.001
 Gender (male = 1) 1.67 (0.87–3.20) 0.126
  1. ACEIs, angiotensin converting enzyme inhibitors; ARBs, angiotensin receptor blockers; CVD, cardiovascular disease; DPP4, dipeptidyl peptidase 4, CI, confidence interval; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; HR, hazard ratio